Showing 1 - 13 results of 13 for search 'Yuanmei Zhu', query time: 0.04s Refine Results
  1. 1
    Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives

    Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives by Hongliang Jin, Yani Gong, Lin Cheng, Yuanmei Zhu, Zheng Zhang, Yuxian He

    Published 2023-12-01
    Get full text
    Article
  2. 2
    In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor

    In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor by Yue Hu, Wenjiang Yu, Xiuzhu Geng, Yuanmei Zhu, Huihui Chong, Yuxian He

    Published 2022-06-01
    Get full text
    Article
  3. 3
    Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif

    Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif by Tong Wu, Yuanmei Zhu, Nian Liu, Yue Hu, Huihui Chong, Yuxian He

    Published 2022-10-01
    Get full text
    Article
  4. 4
    SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses

    SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses by Yuanmei Zhu, Danwei Yu, Yue Hu, Tong Wu, Huihui Chong, Yuxian He

    Published 2021-08-01
    Get full text
    Article
  5. 5
    Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus

    Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus by Danwei Yu, Yuanmei Zhu, Hongxia Yan, Tong Wu, Huihui Chong, Yuxian He

    Published 2021-01-01
    Get full text
    Article
  6. 6
    Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41

    Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41 by Hongxia Yan, Hongxia Yan, Tong Wu, Tong Wu, Yue Chen, Yue Chen, Hongliang Jin, Hongliang Jin, Li Li, Yuanmei Zhu, Yuanmei Zhu, Huihui Chong, Huihui Chong, Yuxian He, Yuxian He

    Published 2022-05-01
    Get full text
    Article
  7. 7
    Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors

    Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors by Danwei Yu, Yang Su, Xiaohui Ding, Yuanmei Zhu, Bo Qin, Huihui Chong, Sheng Cui, Yuxian He

    Published 2020-03-01
    Get full text
    Article
  8. 8
    Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy

    Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy by Yue Chen, Hongliang Jin, Xiaoran Tang, Li Li, Xiuzhu Geng, Yuanmei Zhu, Huihui Chong, Yuxian He

    Published 2022-12-01
    Get full text
    Article
  9. 9
    Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors

    Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors by Xiuzhu Geng, Zixuan Liu, Danwei Yu, Bo Qin, Yuanmei Zhu, Sheng Cui, Huihui Chong, Yuxian He

    Published 2019-07-01
    Get full text
    Article
  10. 10
    Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques.

    Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. by Huihui Chong, Jing Xue, Yuanmei Zhu, Zhe Cong, Ting Chen, Qiang Wei, Chuan Qin, Yuxian He

    Published 2019-02-01
    Get full text
    Article
  11. 11
    SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron

    SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron by Yuanmei Zhu, Xiaojing Dong, Nian Liu, Tong Wu, Huihui Chong, Xiaobo Lei, Lili Ren, Jianwei Wang, Yuxian He

    Published 2022-12-01
    Get full text
    Article
  12. 12
    Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket

    Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket by Xiujuan Zhang, Xiujuan Zhang, Yuanmei Zhu, Hao Hu, Senyan Zhang, Pengfei Wang, Huihui Chong, Jinsheng He, Xinquan Wang, Yuxian He

    Published 2018-02-01
    Get full text
    Article
  13. 13
    Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants

    Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants by Danwei Yu, Yuanmei Zhu, Tao Jiao, Tong Wu, Xia Xiao, Bo Qin, Huihui Chong, Xiaobo Lei, Lili Ren, Sheng Cui, Jianwei Wang, Yuxian He

    Published 2021-01-01
    Get full text
    Article

Search Tools: